Drug intelligence / Profile preview

MD-Knee

Development stage: Unknown
Lead developer: Guna
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Intraarticular

Overview

MD-Knee is an injectable medical device containing purified porcine collagen, developed by Guna S.p.a. for the management of knee osteoarthritis. It is designed to provide mechanical support to the joint, acting as a bio-scaffold that stabilizes the joint capsule and ligaments. By improving the histological structure of the collagen fibers in the joint, it helps to reduce pain and improve mobility. Clinical evidence from randomized controlled trials indicates that MD-Knee is non-inferior to sodium hyaluronate (viscosupplementation) in alleviating symptoms of knee osteoarthritis over a six-month period. The collagen used has a molecular weight of approximately 300,000 daltons and is produced through tangential filtration to ensure purity.

Brand names: MD-Knee
Other names: Guna MD-Knee

Beyond the preview

Go deeper on MD-Knee.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD-Knee.

Explore the full profile